Metabolic therapeutics in angina pectoris: history revisited with perhexiline.

Sally Inglis, Simon Stewart

Journal: European journal of cardiovascular nursing 2006;5(2):175-84

PMID: 16469541

Abstract

The ever-increasing burden of ischaemic heart disease and its common manifestation chronic angina pectoris calls for the exploration of other treatment options for those patients who despite the maximum conventional pharmacological and surgical interventions continue to suffer. Such exploration has led to the increasing use of new metabolically acting antianginal agents and the re-emergence of an old and somewhat forgotten pharmacological agent, perhexiline maleate. This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir.

Address: Faculty of Health Sciences, University of Queensland, Australia.

DOI: 10.1016/j.ejcnurse.2006.01.001

Link outs

Free resources

Medical:

https://medlineplus.gov/angina.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

MeSH Terms: Acetanilides, Angina Pectoris, Calcium Channel Blockers, Cardiovascular Agents, Carnitine O-Palmitoyltransferase, Drug Monitoring, Epoxy Compounds, Fatty Acids, Half-Life, Humans, Metabolic Clearance Rate, Nurse's Role, Nursing Assessment, Patient Education as Topic, Patient Selection, Perhexiline, Piperazines, Randomized Controlled Trials as Topic, Ranolazine, Treatment Outcome, Trimetazidine, Vasodilator Agents